journal article·2025-09

Lipid‐like Carbon‐Dot Liposomes for Enhanced Drug Delivery and Membrane Fluidity Modulation in the Treatment of Metastatic Triple‐Negative Breast Cancer

Yu‐Feng Lin, Ren‐Siang Wu, Yu‐Syuan Lin, Kai‐Min Chan, Pei‐Feng Chen, Tzu‐Yun Huang, Chih‐Ching Huang, Robert Y.‐L. Wang, Hsu‐Huan Chou, Yu‐Fen Huang, Huan‐Tsung Chang

Small· Volume 21· Issue 38
Publisher page

Abstract

Abstract Cancer metastasis remains a major clinical challenge, leading to discouraging treatment outcomes and over 90% of cancer‐related mortality. In this study, lipid‐like carbon dots (LCDs) are designed to self‐assemble into liposome‐like structures, namely carbon‐dot liposomes (CDsomes), serving as a multifunctional drug carrier for anticancer and anti‐metastasis therapy in highly invasive triple‐negative breast cancer (TNBC). The amphiphilic nature of CDsomes enables efficient fusion with TNBC cell membranes, facilitating drug delivery while reducing membrane fluidity. This modulation significantly suppresses TNBC cell invasion, migration, and metastasis both in vitro and in vivo . The unilamellar structure of CDsomes allows efficient encapsulation of anticancer drugs with varying polarities, including doxorubicin (Dox), carfilzomib, docetaxel, gemcitabine, and cisplatin. CDsomes also promote tumor penetration and Dox accumulation through the enhanced permeability and retention effect, along with their inherent elastic and lipophilic properties. Consequently, Dox‐loaded CDsomes (Dox@CDsomes) exhibit superior antitumor and anti‐metastatic efficacy and improved survival rates compared to free Dox in an orthotopic TNBC model while ameliorating systemic toxicity. Notably, Dox@CDsomes achieve therapeutic outcomes comparable to commercial liposomal Dox (Doxil) while extending survival rates by 20%. These findings highlight CDsomes‐mediated membrane fluidity modulation as a promising therapeutic strategy for metastasis suppression, offering new avenues in multimodal cancer therapies.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Carbon and Quantum Dots Applications · Advanced biosensing and bioanalysis techniques · Luminescence and Fluorescent Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry National Taiwan University Taipei 10617 Taiwan

Division of Microbiology and Immunology Graduate Institute of Biomedical Sciences College of Medicine Chang Gung University Taoyuan 33302 Taiwan

Department of Biomedical Engineering and Environmental Sciences National Tsing Hua University Hsinchu 30013 Taiwan

Institute of Analytical and Environmental Sciences National Tsing Hua University Hsinchu 30013 Taiwan

Department of Bioscience and Biotechnology National Taiwan Ocean University Keelung 20224 Taiwan

Center of Excellence for the Oceans National Taiwan Ocean University Keelung 20224 Taiwan

School of Pharmacy College of Pharmacy Kaohsiung Medical University Kaohsiung 80708 Taiwan

Department of Biomedical Sciences College of Medicine Chang Gung University Taoyuan 33302 Taiwan

Division of Pediatric Infectious Disease Department of Pediatrics Chang Gung Memorial Hospital Linkuo Taoyuan 33305 Taiwan

Kidney Research Center and Department of Nephrology Chang Gung Memorial Hospital Linkuo Taoyuan 33305 Taiwan

Division of Breast Surgery Department of General Surgery Chang Gung Memorial Hospital Linkou Taoyuan 33305 Taiwan

Graduate Institute of Clinical Medical Sciences College of Medicine Chang Gung University Taoyuan 33302 Taiwan

Center for Advanced Biomaterials and Technology Innovation Chang Gung University Taoyuan 33302 Taiwan

Funding

National Science and Technology Council · Chang Gung Memorial Hospital, Linkou

References (74)

Show source-provided references
1. 10.1038/s41392-020-0134-x10.1038/s41392-020-0134-x ↗
2. 10.1038/nrclinonc.2016.6610.1038/nrclinonc.2016.66 ↗
3. 10.1038/cr.2017.13310.1038/cr.2017.133 ↗
4. 10.1038/s41421-020-00233-210.1038/s41421-020-00233-2 ↗
5. 10.1007/s10863-020-09846-410.1007/s10863-020-09846-4 ↗
6. 10.1016/j.cmet.2022.09.02310.1016/j.cmet.2022.09.023 ↗
7. 10.1038/onc.2014.5510.1038/onc.2014.55 ↗
8. 10.1371/journal.pone.005080410.1371/journal.pone.0050804 ↗
9. 10.1016/j.ctrv.2016.10.00810.1016/j.ctrv.2016.10.008 ↗
10. 10.3390/ijms1912387110.3390/ijms19123871 ↗
11. 10.3389/fphar.2015.0028610.3389/fphar.2015.00286 ↗
12. 10.1186/s12645-019-0055-y10.1186/s12645-019-0055-y ↗
13. 10.1146/annurev.bb.07.060178.00225110.1146/annurev.bb.07.060178.002251 ↗
14. 10.1016/S0169-409X(99)00037-X10.1016/S0169-409X(99)00037-X ↗
15. 10.1248/bpb.b13-0005910.1248/bpb.b13-00059 ↗
16. Jin Q. · ACS Nano · 2019 · 13 · 954
17. 10.1016/j.jconrel.2022.02.00410.1016/j.jconrel.2022.02.004 ↗
18. 10.1021/acs.langmuir.4c0266410.1021/acs.langmuir.4c02664 ↗
19. 10.1080/14686996.2019.162717410.1080/14686996.2019.1627174 ↗
20. 10.3389/fonc.2020.60503710.3389/fonc.2020.605037 ↗
21. 10.1016/j.jddst.2025.10663810.1016/j.jddst.2025.106638 ↗
22. 10.1021/acscentsci.6b0017210.1021/acscentsci.6b00172 ↗
23. 10.1021/acsnano.3c0534110.1021/acsnano.3c05341 ↗
24. 10.1021/acs.accounts.3c0076910.1021/acs.accounts.3c00769 ↗
25. 10.1016/j.addr.2021.11397410.1016/j.addr.2021.113974 ↗
26. 10.1038/s41571-022-00699-x10.1038/s41571-022-00699-x ↗
27. 10.1016/j.mattod.2021.07.02810.1016/j.mattod.2021.07.028 ↗
28. 10.1002/smll.20140264810.1002/smll.201402648 ↗
29. 10.1002/smll.20180508710.1002/smll.201805087 ↗
30. 10.1016/j.carbon.2020.06.02410.1016/j.carbon.2020.06.024 ↗
31. 10.1002/smll.20230377310.1002/smll.202303773 ↗
32. 10.1021/acsomega.9b0430110.1021/acsomega.9b04301 ↗
33. 10.1002/wnan.161710.1002/wnan.1617 ↗
34. 10.1002/sstr.20220003310.1002/sstr.202200033 ↗
35. 10.1016/j.ccr.2025.21655210.1016/j.ccr.2025.216552 ↗
36. 10.1002/adhm.20200060710.1002/adhm.202000607 ↗
37. 10.1016/j.cej.2020.12421210.1016/j.cej.2020.124212 ↗
38. 10.1002/anie.20190300510.1002/anie.201903005 ↗
39. 10.1039/C7NR03658B10.1039/C7NR03658B ↗
40. 10.1039/D0FO01350A10.1039/D0FO01350A ↗
41. 10.1002/advs.20200240410.1002/advs.202002404 ↗
42. 10.1021/acsami.7b1496910.1021/acsami.7b14969 ↗
43. 10.1016/j.jcis.2022.08.00310.1016/j.jcis.2022.08.003 ↗
44. 10.1016/j.carbon.2022.10.00810.1016/j.carbon.2022.10.008 ↗
45. 10.1016/j.jcis.2020.09.06210.1016/j.jcis.2020.09.062 ↗
46. 10.1002/adma.20170474010.1002/adma.201704740 ↗
47. 10.1016/S0006-3495(95)80418-210.1016/S0006-3495(95)80418-2 ↗
48. 10.1039/C4NJ01185F10.1039/C4NJ01185F ↗
49. 10.1201/b1171210.1201/b11712 ↗
50. 10.1007/s10895-018-2209-410.1007/s10895-018-2209-4 ↗
51. 10.1021/la011008510.1021/la0110085 ↗
52. 10.1021/acsomega.7b0123510.1021/acsomega.7b01235 ↗
53. 10.1007/s13197-020-04360-210.1007/s13197-020-04360-2 ↗
54. 10.1080/10717544.2019.158273010.1080/10717544.2019.1582730 ↗
55. 10.1016/j.ajps.2013.07.00110.1016/j.ajps.2013.07.001 ↗
56. 10.1016/j.bios.2022.11436210.1016/j.bios.2022.114362 ↗
57. 10.1073/pnas.181892411610.1073/pnas.1818924116 ↗
58. 10.1016/j.tibs.2023.08.00410.1016/j.tibs.2023.08.004 ↗
59. 10.1038/nprot.2011.41910.1038/nprot.2011.419 ↗
60. 10.1016/j.bpj.2012.12.05710.1016/j.bpj.2012.12.057 ↗
61. 10.1007/978-1-4939-1752-5_810.1007/978-1-4939-1752-5_8 ↗
62. 10.1007/s00249-011-0741-010.1007/s00249-011-0741-0 ↗
63. 10.1038/nnano.2012.10910.1038/nnano.2012.109 ↗
64. 10.3389/fcell.2019.0010710.3389/fcell.2019.00107 ↗
65. 10.1007/978-1-60761-609-2_1410.1007/978-1-60761-609-2_14 ↗
66. 10.1016/j.trecan.2017.04.00810.1016/j.trecan.2017.04.008 ↗
67. 10.3390/pharmaceutics1004019310.3390/pharmaceutics10040193 ↗
68. 10.1089/ten.tec.2015.028010.1089/ten.tec.2015.0280 ↗
69. 10.1039/C8NR09381D10.1039/C8NR09381D ↗
70. 10.1016/j.addr.2019.01.00210.1016/j.addr.2019.01.002 ↗
71. 10.1016/j.bioactmat.2020.04.01010.1016/j.bioactmat.2020.04.010 ↗
72. 10.1002/adfm.20170005610.1002/adfm.201700056 ↗
73. 10.1016/j.sjbs.2020.07.01110.1016/j.sjbs.2020.07.011 ↗
74. 10.1152/ajpheart.00290.201810.1152/ajpheart.00290.2018 ↗